欧康医药
(833230)
| 流通市值：8.19亿 | | | 总市值：17.62亿 |
| 流通股本：3593.00万 | | | 总股本：7726.73万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 58,372,908.24 | 310,268,218.29 | 223,826,491.38 | 132,309,174.89 |
| 营业收入 | 58,372,908.24 | 310,268,218.29 | 223,826,491.38 | 132,309,174.89 |
| 二、营业总成本 | 57,115,920.15 | 284,243,069.64 | 201,402,456.95 | 118,189,219.05 |
| 营业成本 | 48,460,579.53 | 245,579,306.41 | 177,890,087.59 | 104,758,943.25 |
| 税金及附加 | 34,544.58 | 1,536,294.04 | 844,855.75 | 844,849.83 |
| 销售费用 | 1,514,227.94 | 7,646,551.59 | 2,928,687.34 | 1,377,754.9 |
| 管理费用 | 5,156,552.46 | 18,425,754.01 | 10,447,827.51 | 6,733,150.21 |
| 研发费用 | 1,776,849.66 | 11,328,812.51 | 9,025,240.8 | 4,408,237.31 |
| 财务费用 | 173,165.98 | -273,648.92 | 265,757.96 | 66,283.55 |
| 其中:利息费用 | 186,961.58 | 387,128.51 | 337,056.61 | 154,011.68 |
| 其中:利息收入 | -2,928.39 | 126,775.26 | -120,423.96 | 114,155.64 |
| 加:公允价值变动收益 | 174,065.36 | 226,447.55 | - | 91,426.13 |
| 加:投资收益 | 4,921.43 | 944,982.92 | 879,108.01 | 693,879.42 |
| 汇兑收益 | - | - | 325,511.32 | 304,451.94 |
| 资产处置收益 | - | -885,060.79 | -635,689.34 | -29,461.91 |
| 资产减值损失(新) | - | -2,605,981.05 | -2,002,103.3 | -449,098.92 |
| 信用减值损失(新) | 20,000 | 796,119.7 | 718,788.91 | 1,140,300.91 |
| 其他收益 | 418,343.58 | 1,947,668.64 | 1,971,098.42 | 1,350,636.5 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,874,318.46 | 26,449,325.62 | 23,680,748.45 | 17,222,089.91 |
| 加:营业外收入 | 1,708.19 | 4,075.19 | 2,007.48 | 1,565 |
| 减:营业外支出 | 0.01 | 162,741.14 | 162,741.14 | 162,741.14 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,876,026.64 | 26,290,659.67 | 23,520,014.79 | 17,060,913.77 |
| 减:所得税费用 | 325,915.71 | 4,174,808.49 | 4,265,220.03 | 3,435,764.14 |
| 六、净利润 | 1,550,110.93 | 22,115,851.18 | 19,254,794.76 | 13,625,149.63 |
| 持续经营净利润 | 1,550,110.93 | 22,115,851.18 | 19,254,794.76 | 13,625,149.63 |
| 归属于母公司股东的净利润 | 1,672,606.52 | 22,442,322.98 | 19,526,091.61 | 13,847,503.44 |
| 少数股东损益 | -122,495.59 | -326,471.8 | -271,296.85 | -222,353.81 |
| (一)基本每股收益 | 0.02 | 0.3 | 0.26 | 0.18 |
| (二)稀释每股收益 | 0.02 | 0.3 | 0.26 | 0.18 |
| 八、其他综合收益 | - | -40,712.59 | 49,822.77 | 75,970.96 |
| 归属于母公司股东的其他综合收益 | - | -32,570.07 | 49,822.77 | 75,970.96 |
| 九、综合收益总额 | 1,550,110.93 | 22,075,138.59 | 19,304,617.53 | 13,701,120.59 |
| 归属于母公司股东的综合收益总额 | 1,672,606.52 | 22,409,752.91 | 19,575,914.38 | 13,923,474.4 |
| 归属于少数股东的综合收益总额 | -122,495.59 | -334,614.32 | -271,296.85 | -222,353.81 |
| 公告日期 | 2025-04-28 | 2025-04-17 | 2024-10-30 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |